Context Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied clinically will provide further benefit in stable coronary artery […]
Objectives This study was undertaken to evaluate the efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. Background Familial hypercholesterolemia is a common […]
Background Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a sub- stantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, […]
Context Children with familial hypercholesterolemia have endothelial dysfunction and increased carotid intima-media thickness (IMT), which herald the premature ath- erosclerotic disease they develop later in […]
Background Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, […]
Background Torcetrapib, an inhibitor of cholesteryl ester transfer protein, may reduce atheroscle- rotic vascular disease by increasing levels of high-density lipoprotein (HDL) choles- terol. Methods […]
Background Despite the prognostic value of metabolic syndrome for predicting cardiovascular events, few trials have investigated the effects of statin therapy on cardiovascular morbidity and […]
Background A multicenter, randomized, double-blind, placebo-controlled study was conducted to evaluate LDL cholesterol–lowering efficacy, overall safety, and tolerability and the influence on growth and pubertal […]